Table 2. Oxylipin concentrations in BALF from 1) Healthy controls 2) Asthmatic controls and 3) Asthmatics following provocation.

PUFAa	Oxylipinb (pM)	Healthy controls (HC)		Asthmatic controls (AC)		Asthmatics following provocation (AFP)		Significancec
								HC/AC	HC/AFP	AC/AFP	Trendd
		AVe	CVf	AV	CV	AV	CV	p	p	p	p
AAg	5-HETE	89	66	135	62	131	62	0.20	0.22	0.83	0.071
	12-HETE	32	69	80	51	104	58	0.0081	0.012	0.30	0.022
	15-HETE	337	73	734	66	991	63	0.046	0.022	0.066	0.091
	15-KETE	110	64	252	76	294	62	0.080	0.026	0.28	0.091
	5,6-DiHETE	2.6	89	3.1	65	3.7	74	0.68	0.42	0.48	0.030
	5,15-DiHETE	5.4	98	11	65	12	57	0.085	0.048	0.79	0.028
	11,12-DiHETrE	0.9	82	1.4	41	1.3	74	0.12	0.38	0.62	0.045
	14,15-DiHETrE	2.9	50	3.6	20	3.3	35	0.24	0.57	0.56	0.070
	11(12)-EpETrE	3.2	44	7.6	92	4.0	59	0.12	0.42	0.22	0.39
	LTB4	53	71	72	59	81	53	0.35	0.17	0.44	0.020
	6-trans-LTB4	22	56	32	58	39	45	0.18	0.030	0.051	0.030
	TXB2	41	65	47	52	78	119	0.66	0.30	0.36	0.20
	PGE2	5.1	64	6.1	33	9.8	56	0.44	0.046	0.16	0.040
	PGD2	3.4	84	5.6	75	7.7	89	0.23	0.11	0.52	0.020
LAh	9-HODE	201	66	224	55	190	63	0.73	0.85	0.63	0.20
	9-KODE	129	73	197	77	138	68	0.27	0.84	0.21	0.37
	13-HODE	785	74	1250	60	1530	51	0.17	0.039	0.15	0.022
	EKODE	244	65	541	54	449	55	0.018	0.057	0.41	0.0060
	9,10,13-TriHOME	68	43	122	61	104	25	0.087	0.016	0.52	0.022
	9,12,13-TriHOME	279	46	537	54	516	27	0.043	0.0024	0.85	0.0060
	9,10-DiHOME	221	53	440	69	463	57	0.090	0.039	0.82	0.0030
	9(10)-EpOME	914	27	1370	49	1570	42	0.10	0.026	0.42	0.060
	12,13-DiHOME	235	52	460	74	467	60	0.11	0.057	0.95	0.060
	12(13)-EpOME	1000	30	1540	48	1770	38	0.086	0.16	0.39	0.060
DGLAi	15-HETrE	38	63	81	59	116	71	0.032	0.031	0.18	0.091
α-LAj	9-HOTE	8.0	63	9.4	44	6.8	41	0.56	0.54	0.16	0.41
	13-HOTE	33	70	67	72	76	48	0.083	0.011	0.45	0.022
	12(13)-EpODE	2.3	61	4.3	55	5.0	48	0.048	0.010	0.41	0.0030
EPAk	5-HEPE	8.2	86	13	54	13	65	0.15	0.24	0.68	0.080
	12-HEPE	6.2	52	16	58	17	38	0.021	0.00051	0.71	0.0030
	15-HEPE	32	70	99	70	110	53	0.030	0.0064	0.27	0.091
DHAl	17-HDoHE	162	65	452	76	517	60	0.051	0.014	0.59	0.0030
15-LOXm	ω-6 (n = 10)n	1980	52	3490	46	4000	39	0.034	0.0064	0.29	0.022
	ω-3 (n = 5)	242	60	644	70	727	53	0.040	0.0088	0.55	0.022
	Total 15-LOX (n = 15)	2230	52	4130	47	4720	41	0.025	0.0049	0.31	0.022

^aPolyunsaturated fatty acid.

^bOxylipin levels are reported as concentration (pM) and were normalized to the BAL volume recoveries. A complete list of all oxylipin acronyms is provided in Table S1.

^cStatistical significance was calculated with either an unpaired or paired Student's t-test. Values with p<0.05 are shown in italics with two significant figures.

^dThe median concentration (pM) among the healthy controls (HC) regarding each oxylipin was used as a cut off limit for all three groups (i.e., Healthy Controls, Asthmatic Controls and Asthmatics Following Provocation), with values provided in Table S8. All p-values regarding trend are one-sided.

^eAverage,

^fCoefficient of variance,

^gArachidonic acid,

^hLinoleic Acid,

ⁱDihomo-γ-linolenic acid,

^jα-Linolenic acid,

^kEicosapentaenoic acid,

^lDocosahexaenoic acid.

^m15-Lipoxygenase products.

ⁿThe numbers in parentheses indicate the number of oxylipin species analyzed for each subgroup.